Stericycle, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Stericycle, Inc. (SRCL) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Stericycle, Inc. (NasdaqGS: SRCL) violated federal securities laws by issuing materially misleading business information to the investing public. Stericycle, together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally.

Stericycle May Have Engaged in Illegal Billing Practices

Stericycle is currently the subject of a federal securities fraud class action lawsuit and several consumer class action lawsuits alleging that the company used buried language in its service agreements to unlawfully impose automatic price increases on its customers in violation of the contracts’ terms. On February 16, 2017, Judge Milton I. Shadur of the U.S. District Court for the Northern District of Illinois granted class certification in a $608 million multidistrict litigation against Stericycle, saying that the class members had common ground in their complaints of fraudulent overcharges.

Stericycle Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: